113 related articles for article (PubMed ID: 21159885)
1. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients.
Sorrentino C; Musiani P; Pompa P; Cipollone G; Di Carlo E
Clin Cancer Res; 2011 Mar; 17(6):1571-81. PubMed ID: 21159885
[TBL] [Abstract][Full Text] [Related]
2. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
3. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.
Mori R; Dorff TB; Xiong S; Tarabolous CJ; Ye W; Groshen S; Danenberg KD; Danenberg PV; Pinski JK
Prostate; 2010 Nov; 70(15):1692-700. PubMed ID: 20564320
[TBL] [Abstract][Full Text] [Related]
4. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
[TBL] [Abstract][Full Text] [Related]
5. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
6. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
7. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
8. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
[TBL] [Abstract][Full Text] [Related]
9. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
11. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.
Mink SR; Hodge A; Agus DB; Jain A; Gross ME
Prostate; 2010 Aug; 70(11):1201-10. PubMed ID: 20564426
[TBL] [Abstract][Full Text] [Related]
12. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
Rigaud J; Tiguert R; Decobert M; Hovington H; Latulippe E; Laverdiere J; Larue H; Lacombe L; Fradet Y
Prostate; 2004 Feb; 58(3):269-76. PubMed ID: 14743466
[TBL] [Abstract][Full Text] [Related]
13. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
Furukawa J; Miyake H; Takenaka A; Hara I; Fujisawa M
BJU Int; 2007 Aug; 100(2):310-4. PubMed ID: 17511772
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer does not influence androgen levels: a radical prostatectomy cohort study.
De Nunzio C; Carluccini A; Cicione A; Squillacciotti S; Trucchi A; Cantiani A; Leonardo C; Tubaro A
Urol Int; 2011; 86(2):161-6. PubMed ID: 21252482
[TBL] [Abstract][Full Text] [Related]
15. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.
Lin DW; Coleman IM; Hawley S; Huang CY; Dumpit R; Gifford D; Kezele P; Hung H; Knudsen BS; Kristal AR; Nelson PS
J Clin Oncol; 2006 Aug; 24(23):3763-70. PubMed ID: 16822846
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
[TBL] [Abstract][Full Text] [Related]
17. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer.
Amling CL; Blute ML; Bergstralh EJ; Slezak JM; Martin SK; Zincke H
Semin Urol Oncol; 1997 Nov; 15(4):222-9. PubMed ID: 9421449
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation.
Spahn M; Weiss C; Bader P; Ströbel P; Gerharz EW; Kneitz B; Frohneberg D
Urol Int; 2010; 84(2):164-73. PubMed ID: 20215820
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
Gannon PO; Poisson AO; Delvoye N; Lapointe R; Mes-Masson AM; Saad F
J Immunol Methods; 2009 Aug; 348(1-2):9-17. PubMed ID: 19552894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
